Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965489 | 1.00 | PIM3 (0.32) | PIM3POLBSMN1; SMN2PHGDHMCL1 | |
| SCHEMBL962381 | 0.88 | PIM3 (0.41) | PIM3PHGDHMCL1 | |
| SCHEMBL962382 | 0.88 | PIM3 (0.41) | PIM3PHGDHMCL1 | |
| SCHEMBL964596 | 0.86 | ABL1 (0.35) | PIM3PHGDH | |
| SCHEMBL964595 | 0.86 | ABL1 (0.35) | PIM3PHGDH | |
| SCHEMBL4553102 | 0.85 | ALDH1A1 (0.37) | PIM3SMN1; SMN2MCL1 | |
| SCHEMBL4553100 | 0.85 | ALDH1A1 (0.37) | PIM3SMN1; SMN2MCL1 | |
| SCHEMBL965488 | 0.85 | POLB (0.34) | PIM3POLBSMN1; SMN2PHGDH | |
| SCHEMBL963542 | 0.84 | MTNR1A (0.41) | POLBMCL1 | |
| SCHEMBL963543 | 0.84 | MTNR1A (0.41) | POLBMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | PIM3 3705/4885POLB 1580/4885SMN1; SMN2 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.